Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684801 | 0.78 | — | — | |
| SCHEMBL7729836 | 0.77 | KDM4E (0.37) | MMP12LMNAKDM4EALDH1A1TDP1 | |
| SCHEMBL6836071 | 0.72 | KDM4E (0.32) | KDM4EALDH1A1ALOX15POLB | |
| SCHEMBL12634096 | 0.71 | KDM4E (0.39) | LMNAKDM4EALDH1A1TDP1ALOX15 | |
| SCHEMBL19096411 | 0.70 | FOLH1 (0.38) | LMNAKDM4EALDH1A1TDP1PKM | |
| SCHEMBL899835 | 0.70 | KDM4E (0.42) | LMNAKDM4EALDH1A1TDP1ALOX15 | |
| SCHEMBL4786418 | 0.69 | KDM4E (0.44) | KDM4EALDH1A1TDP1MEN1KMT2A | |
| SCHEMBL13346543 | 0.69 | ALDH1A1 (0.39) | LMNAKDM4EALDH1A1TDP1ALOX15 | |
| SCHEMBL3680119 | 0.69 | KDM4E (0.44) | LMNAKDM4EALDH1A1TDP1ALOX15 | |
| SCHEMBL4742262 | 0.69 | KDM4E (0.41) | LMNAKDM4EALDH1A1TDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149826-B1 | Ester compounds having alicyclic structure, and methods for preparing the same | SHINETSU CHEMICAL CO (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-6403823-B2 | Ester compounds having alicyclic structure and method for preparing same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20010051742-A1 | Novel ester compounds having alicyclic structure and method for preparing same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2001-12-13 | — | — | US | disclosed |
| EP-1149826-A2 | Ester compounds having alicyclic structure, and methods for preparing the same | Shin-Etsu Chemical Co., Ltd. (JP) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051742-A1 | Novel ester compounds having alicyclic structure and method for preparing same | ARCN1, ECH1, GAR1 | MMP12 4274/4885LMNA 218/4885SMN1; SMN2 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.